Kuan-Yu Liu

University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA.

IPG DXTRA Entertainment, Inc. operates as a public relations, marketing, and consulting agency. It serves actors, actresses, musicians, films, production companies, TV properties, authors, and content creators. The company is headquartered in Los Angeles, CA.

MicroTransponder, Inc. develops wireless neurostimulation system for the treatment of chronic pain and other neurological indications. It is a medical device company spun out from the University of Texas at Dallas. The firm has an team of neuroengineers collaborating with academics to develop wireless solutions to treat neurological diseases. The company was founded by Lawrence James Cauller, Thomas James Curnes II and William Michael Rosellini in June 2009 and is headquartered in Austin, TX.

Rosellini Scientific LLC develops medical rehabilitation devices. The private company is based in Lexington, KY and has subsidiaries in the United States. The company was founded by William Michael Rosellini.

Part of Marathon Digital Holdings, Inc., Sarif Biomedical LLC is a company that manufactures surgery related equipment. The company is based in Tool, TX. Sarif Biomedical was acquired by Marathon Digital Holdings, Inc. on May 02, 2014 for $0.55 million.

Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021.